July 31, 2023 02:12 PM EDTUpdated 03:08 PM
FDA+

FDA ap­proves GSK's Jem­per­li for front­line use in cer­tain ad­vanced en­dome­tri­al can­cers

Zachary Brennan

Senior Editor

GSK’s new can­cer drug Jem­per­li (dostar­limab) won an FDA ap­proval on Mon­day, al­most two months ahead of its PDU­FA date, for use in cer­tain front­line …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

FDA re­jects Astel­las’ ef­fort to sup­port longer use of eye drug Iz­er­vay 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times